1 active not recruiting, 1 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow eplontersen: new trials by email Literature Review of eplontersen trials Research Report on eplontersen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM Eplontersen, ALXN2220, Placebo - Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Phase 2 | Active not recruiting | AstraZeneca | 326 | 2026-06-11 | 2026-07-14 |
| Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ). ION-682884, Placebo, Vitamin A - Healthy Volunteers, hATTR Amyloidosis | Phase 1 / Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 47 | 2018-12-21 | 2022-12-19 |
AstraZeneca (1) · Ionis Pharmaceuticals, Inc. (1)
Canada (2) · China (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Spain (1) · Sweden (1) · United Kingdom (1) · United States (1)